On the morning of the second day of the 2025 National Conference: Concentrated negotiations on tumor drugs, Astrazeneca, Roche, and others participate

From the on-site negotiations of the national medical insurance catalog and the price negotiations for innovative drugs with commercial insurance in 2025, it was learned that the second day's process of the national negotiations began around 8 a.m. today, with anti-tumor drugs and chronic disease medications being the main varieties for negotiation. Representatives from companies such as AstraZeneca, KELUN PHARMA, Roche, and Sanofi have entered the negotiation venue. A representative from a negotiating company expressed to reporters their personal opinion that "those with a higher likelihood will be discussed first, while those with a slightly lower likelihood will be arranged later."